430 related articles for article (PubMed ID: 34590460)
1. Molecular subtype classification of breast cancer using established radiomic signature models based on
Liu J; Bian H; Zhang Y; Gao Y; Yin G; Wang Z; Li X; Ma W; Xu W
Front Biosci (Landmark Ed); 2021 Aug; 26(9):475-484. PubMed ID: 34590460
[No Abstract] [Full Text] [Related]
2. Predictive value of radiomic signature based on 2-[
Liu J; Zhang Z; Bian H; Zhang Y; Ma W; Wang Z; Yin G; Dai D; Chen W; Zhu L; Xu W; Zhang H; Li X
Eur J Radiol; 2023 Oct; 167():111050. PubMed ID: 37598640
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Tumor Burden Assessed by Dual Time Point [
Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
[TBL] [Abstract][Full Text] [Related]
4. Predictive Power of a Radiomic Signature Based on
Li X; Yin G; Zhang Y; Dai D; Liu J; Chen P; Zhu L; Ma W; Xu W
Front Oncol; 2019; 9():1062. PubMed ID: 31681597
[TBL] [Abstract][Full Text] [Related]
5. Ability of
Ou X; Wang J; Zhou R; Zhu S; Pang F; Zhou Y; Tian R; Ma X
Contrast Media Mol Imaging; 2019; 2019():4507694. PubMed ID: 30930700
[No Abstract] [Full Text] [Related]
6. Radiomics based on
Ou X; Zhang J; Wang J; Pang F; Wang Y; Wei X; Ma X
Cancer Med; 2020 Jan; 9(2):496-506. PubMed ID: 31769230
[TBL] [Abstract][Full Text] [Related]
7. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
8. Value of pre-therapy
Zhang J; Zhao X; Zhao Y; Zhang J; Zhang Z; Wang J; Wang Y; Dai M; Han J
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1137-1146. PubMed ID: 31728587
[TBL] [Abstract][Full Text] [Related]
9. PET/MRI and PET/CT Radiomics in Primary Cervical Cancer: A Pilot Study on the Correlation of Pelvic PET, MRI, and CT Derived Image Features.
Esfahani SA; Torrado-Carvajal A; Amorim BJ; Groshar D; Domachevsky L; Bernstine H; Stein D; Gervais D; Catalano OA
Mol Imaging Biol; 2022 Feb; 24(1):60-69. PubMed ID: 34622425
[TBL] [Abstract][Full Text] [Related]
10. Combined
Wu J; Zhang X; Jia Z; Zhou X; Qi R; Ji H; Sun J; Sun C; Teng Z; Lu G; Chen X
Mol Pharm; 2022 Sep; 19(9):3405-3411. PubMed ID: 35972444
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
[TBL] [Abstract][Full Text] [Related]
12. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?
Groheux D; Majdoub M; Tixier F; Le Rest CC; Martineau A; Merlet P; Espié M; de Roquancourt A; Hindié E; Hatt M; Visvikis D
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1682-1691. PubMed ID: 26140849
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of
Nakajo M; Takeda A; Katsuki A; Jinguji M; Ohmura K; Tani A; Sato M; Yoshiura T
Br J Radiol; 2022 Jun; 95(1134):20211050. PubMed ID: 35312337
[TBL] [Abstract][Full Text] [Related]
14.
Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
[TBL] [Abstract][Full Text] [Related]
15. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
[TBL] [Abstract][Full Text] [Related]
16. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
17. Predictive Value of Metabolic Parameters Derived From
Liu H; Ye Z; Yang T; Xie H; Duan T; Li M; Wu M; Song B
Front Immunol; 2021; 12():724464. PubMed ID: 34512653
[TBL] [Abstract][Full Text] [Related]
18. Quantitative classification and radiomics of [
de Koster EJ; Noortman WA; Mostert JM; Booij J; Brouwer CB; de Keizer B; de Klerk JMH; Oyen WJG; van Velden FHP; de Geus-Oei LF; Vriens D;
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2174-2188. PubMed ID: 35138444
[TBL] [Abstract][Full Text] [Related]
19. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
20. Value of [
Li K; Sun H; Lu Z; Xin J; Zhang L; Guo Y; Guo Q
Eur J Radiol; 2018 Sep; 106():160-166. PubMed ID: 30150039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
